Izrael - angol - Ministry of Health

bayer israel ltd - ethinylestradiol; gestodene - coated tablets - ethinylestradiol 0.03 mg; gestodene 0.075 mg - ethinylestradiol - ethinylestradiol - hormonal contraception.

Izrael - angol - Ministry of Health

bayer israel ltd - ethinylestradiol; levonorgestrel - coated tablets - levonorgestrel 150 mcg; ethinylestradiol 30 mcg - progestogens and estrogens, fixed combinations - oral contraceptive.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - levonorgestrel, quantity: 150 microgram; ethinylestradiol, quantity: 30 microgram - tablet, film coated - excipient ingredients: lactose; hypromellose; microcrystalline cellulose; magnesium stearate; polysorbate 80; titanium dioxide; macrogol 400; allura red ac aluminium lake; brilliant blue fcf aluminium lake - seasonique is indicated for use as an oral contraceptive.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 20 microgram; drospirenone, quantity: 3 mg - tablet, uncoated - excipient ingredients: magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; purified talc; microcrystalline cellulose - yaz is indicated for use as: - an oral contraceptive. - treatment of moderate acne vulgaris in women who seek oral contraception - treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of yaz for pmdd was not assessed beyond 3 cycles. yaz has not been evaluated for treatment of pms (premenstrual syndrome), see clinical trials.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 0.03 mg; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: titanium dioxide; purified talc; lactose monohydrate; magnesium stearate; hypromellose; microcrystalline cellulose - indications: petibelle is indicated for use as an oral contraceptive.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 0.03 mg; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: lactose monohydrate; purified talc; titanium dioxide; magnesium stearate; hypromellose; microcrystalline cellulose - indications: yasmin is indicated for use as an oral contraceptive.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - levonorgestrel, quantity: 100 microgram; ethinylestradiol, quantity: 20 microgram - tablet, film coated - excipient ingredients: gelatin; macrogol 4000; magnesium stearate; maize starch; lactose monohydrate; titanium dioxide; hypromellose - oral contraception

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ethinylestradiol, quantity: 20 microgram; levonorgestrel, quantity: 100 microgram - tablet, film coated - excipient ingredients: lactose monohydrate; macrogol 1500; magnesium stearate; microcrystalline cellulose; glycol montanate; polacrilin potassium; titanium dioxide; hypromellose; hyprolose; macrogol 400 - 1. the prevention of pregnancy. 2. the treatment of moderate acne vulgaris not controlled with topical preparations in post-menarchal, pre-menopausal women who accept contraception.

Izrael - angol - Ministry of Health

bayer israel ltd - ethinylestradiol; gestodene - coated tablets - ethinylestradiol 0.03 mg; gestodene 0.075 mg - ethinylestradiol - hormonal contraception.

Izrael - angol - Ministry of Health

bayer israel ltd - drospirenone; ethinylestradiol as betadex clathrate; levomefolate calcium; levomefolate calcium - film coated tablets - levomefolate calcium 0.451 mg; ethinylestradiol as betadex clathrate 0.02 mg; drospirenone 3 mg; levomefolate calcium 0.451 mg - estradiol, combinations - - oral contraception. - treatment of symptoms of premenstrual dysphoric disorder (pmdd ) in women who choose to use an oral contraceptive as their method of birth control.- treatment of moderate acne vulgaris in women at least 14 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche. - in women who choose to use an oral contraceptive as their method of contraception, to raise folate levels for the purpose of reducing the risk of a neural tube defect in a pregnancy conceived while taking the product or shortly after discontinuing the product.